Interim Director Sales Training, Europe
Cytokinetics
Zug, Switzerland•Est. $200-$300/hr
Chief Revenue OfficerSales Training
Cytokinetics
Cytokinetics is committed to developing potential medicines for people with diseases of impaired muscle function. Learn more about our medicines and research.
- Est. revenue
- $50M–$100M
- Total raised
- $3.2B
- Latest round
- Post-IPO Equity
- Employees
- 796
Funding & revenue at Cytokinetics
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$50M–$100M
Modeled range, not company-reported
Total capital raised
$3.2B
2 known investors
Latest round
Post-IPO Equity · $805M
May 2026
Publicly traded
CYTK, CYTOKINETICS
IPO Apr 2004
Investors
DeerfieldRoyalty Pharma
Growth signals
How fast Cytokinetics is adding people, roles, and audience.
Employees
796
Reported band 501-1000
LinkedIn followers
49K
+34.6% year over year
Headcount change
- MoM
- -0.5%
- QoQ
- +1.1%
- 6mo
- +7.9%
- YoY
- +20.4%
- 2yr
- +43.9%
-4 people
+9 people
+58 people
+135 people
+243 people
Team composition
Where Cytokinetics concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research16421%
- Support8711%
- Operations638%
- Business Development628%
- Healthcare Services506%
- Sales496%
- Human Resources385%
- Information Technology365%
By region
- United States681
- California, United States401
- San Francisco Bay Area368
- San Francisco, CA107
- South San Francisco, CA85
- Greater Philadelphia60
Inside Cytokinetics
What the business focuses on, where it operates, and how employees rate it.
Specialties
Heart FailureHypertrophic Cardiomyopathy
Categories
BiopharmaBiotechnologyHealth CareBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
NASDAQ
Competitors
Companies in the same market as Cytokinetics.
http://www.cytocentrics.comhttp://www.kenaitx.comhttps://bci-pharma.com/http://www.eikontx.comhttp://xytis.comhttps://cianatx.comhttps://kitherbiotech.comhttps://teamkinetic.co.uk/https://www.celsiege.com/http://cydanco.comhttps://syndevrx.comhttp://www.cardiumthx.comhttp://www.purple-biotech.com/http://cytomics.frhttp://www.sycamorebp.comhttp://www.kinetabio.com
Cytokinetics in the news
Recent coverage picked up alongside the firmographic refresh.
- Cytokinetics to Participate in September Investor Conferences
Sep 2026
- Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)
Sep 2026
- Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing
Sep 2026
- ESC 2026: The drug development readouts that stood out
Sep 2026
- Cytokinetics Insider Sold Shares Worth $702,400, According to a Recent SEC Filing
Aug 2026
- Cytokinetics (CYTK) CEO exercises options, sells 7,500 shares
Aug 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 26, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Cytokinetics, you can claim this page to manage and enhance it.